Radiopharmaceutical developer Navidea Biopharmaceuticals has named chairman Dr. Michael Goldberg as president and CEO.
Currently a managing partner of Montaur Capital Partners, Goldberg has been a member of Navidea's board since November 2013 and also served as interim CEO from May to October 2014. He was also previously chairman and CEO of Emisphere Technologies, a developer of oral delivery technologies for macromolecules, Navidea said.
In a related move, Navidea has appointed current board member Dr. Eric Rowinsky as chairman, replacing Goldberg in that role. Goldberg will remain a board member, according to the firm.
